Creative Touch Permanent Makeup and Aesthetics

All three forms of hyperpigmentation converge on a common molecular event: upregulation of microphthalmia-associated transcription factor (MITF) in melanocytes, which drives expression of the three melanogenic enzymes – tyrosinase (TYR), tyrosinase-related protein 1 (TYRP1), and TYRP2 – that produce and regulate melanin synthesis. What differs between presentations is the upstream signal activating MITF: UV radiation via the α-MSH/MC1R/ cAMP/CREB pathway and the SCF/c-KIT pathway in solar lentigines; oestrogen and progesterone acting on melanogenic enzymes and MITF directly, compounded by UV, in melasma; and prostaglandins, leukotrienes, cytokines, and ROS from the arachidonic acid cascade in post-inflammatory hyperpigmentation. The distinction between epidermal and dermal pigment deposition – and the melanophage entrapment mechanism that makes dermal PIH treatment-resistant – is the single most important assessment variable before selecting any treatment approach.

The Melanogenesis Pathway

Melanin is synthesised in melanocytes within specialised organelles called melanosomes. The pathway begins with tyrosinase – the rate-limiting enzyme of melanogenesis – oxidising tyrosine to L-DOPA and subsequently to dopaquinone. Dopaquinone is then processed through either the eumelanin pathway (brown-black pigment, dominant in darker skin types) or the pheomelanin pathway (red-yellow pigment, dominant in lighter skin types with MC1R variants). ^[7]

MITF is the master transcriptional regulator of this process – it activates transcription of TYR, TYRP1, and TYRP2, and is itself activated by two primary upstream pathways that converge on cAMP/CREB signalling: the α-MSH/MC1R receptor pathway and the SCF/c-KIT tyrosine kinase pathway. Both UV radiation and hormonal stimulation reach melanogenesis primarily through MITF rather than acting directly on the enzymatic machinery. ^[3]

Once melanin is synthesised and packaged into melanosomes, transfer to surrounding keratinocytes occurs via melanocyte dendritic extensions – melanosomes are phagocytosed by keratinocytes through a process regulated by the PAR-2 receptor. ^[6] This transfer step is a distinct therapeutic target: even when melanin synthesis is reduced, abnormal transfer regulation can maintain hyperpigmentation, and vice versa.

Solar Lentigines and UV-Driven Melanogenesis

Solar lentigines are epidermal hyperpigmentation lesions caused by chronic UV exposure, representing both increased melanocyte activity and localised melanocyte proliferation rather than simply increased pigment production from a stable cell population.

UV radiation drives melanogenesis through two converging routes. First, UV-exposed keratinocytes upregulate and release α-MSH, which binds MC1R on adjacent melanocytes, activating the cAMP/CREB/MITF cascade and driving tyrosinase expression. Second, UV induces SCF secretion from both keratinocytes and fibroblasts – SCF binding its c-KIT receptor on melanocytes drives both MITF activation and melanocyte proliferation, increasing the number of pigment-producing cells as well as their output per cell. ^[4] Chronic UV also accumulates direct DNA damage in melanocytes, and the DNA damage response itself activates melanogenesis through p53-mediated POMC/α-MSH upregulation – meaning UV damage and UV-triggered pigmentation are part of the same molecular event.

Solar lentigines are confined to the epidermis and respond predictably to treatments that target epidermal pigment: IPL, thulium fractional laser, and chemical peels that induce controlled desquamation of pigmented corneocytes alongside inhibition of tyrosinase activity at the renewal cycle level.

Melasma: Hormonal, UV, Vascular, and Dermal Mechanisms

Melasma is the most complex and treatment-resistant of the three presentations. Its defining feature is a multifactorial aetiology in which UV and hormonal signals interact synergistically rather than additively, and in which dermal as well as epidermal changes contribute to the presentation.

Hormonal mechanisms: Oestrogen directly stimulates melanogenesis through multiple routes – upregulating α-MSH and its receptor MC1R, enhancing tyrosinase expression, and activating MITF transcription. ^[8] Progesterone acts through a distinct route via PI3K/Akt/GSK3β pathway activation, driving melanogenesis through a non-cAMP mechanism that is not addressed by the same upstream interventions that target UV-driven melanogenesis. Both hormones additionally drive ROS production that creates a positive feedback loop: ROS activates melanogenesis, which generates more oxidative stress, perpetuating the pigment cycle independently of ongoing hormonal or UV stimulation.

Dermal component: Melasma is not purely epidermal. Affected skin shows increased dermal vascularity – elevated VEGF expression – and fibroblast activation in the papillary dermis that upregulates SCF production, providing a sustained paracrine melanogenic signal from the dermis independently of UV or hormonal triggers. ^[2] This dermal component explains why melasma recurs rapidly after surface-level treatment and why purely topical approaches targeting epidermal melanin without addressing the dermal paracrine environment produce temporary rather than durable improvement.

The clinical consequences of this architecture: melasma requires treatment approaches that address the epidermal pigment, the vascular component, the dermal fibroblast signal, and the UV/hormonal triggers simultaneously rather than sequentially. Any single-mechanism approach is treating one facet of a multi-source problem.

Post-Inflammatory Hyperpigmentation: The Arachidonic Acid Route

PIH is mechanistically distinct from both solar lentigines and melasma: its primary trigger is cutaneous inflammation rather than UV or hormonal signals, and the pathway to melanocyte activation runs through the arachidonic acid cascade rather than through MITF-activating growth factor receptors.

Inflammation – from any source – triggers release of prostaglandins E2 and D2, leukotrienes LTC4 and LTD4, thromboxane-2, IL-1, IL-6, TNF, and EGF from inflammatory cells, keratinocytes, and melanocytes. ^[5] These mediators collectively stimulate melanocyte activity and enhance melanosome transfer to surrounding keratinocytes. ROS generated during the inflammatory process additionally activates melanogenesis directly through oxidative pathway engagement, independent of receptor-mediated signalling.

Epidermal vs dermal PIH – the critical distinction: Epidermal PIH represents increased melanin synthesis and transfer within the epidermis and responds to treatments that desquamate pigmented keratinocytes, inhibit tyrosinase activity, and reduce the inflammatory signal driving melanocyte stimulation. Dermal PIH arises when the inflammatory process is severe enough to disrupt the dermo-epidermal junction and basal keratinocyte layer – melanin released from disrupted basal cells is deposited into the papillary dermis where it is engulfed by macrophages, producing melanophages that persist in the dermis independently of any ongoing melanocyte activity. ^[1] Dermal melanophage entrapment is largely irreversible through topical intervention; the pigment is sequestered within macrophage lysosomes where tyrosinase inhibitors and desquamation agents have no access. This makes treatment-triggered PIH in the dermal compartment a distinct risk category.

A clinically important connection: accumulating senescent fibroblasts in photo-damaged dermis secrete pro-inflammatory cytokines that can stimulate abnormal pigmentation independently of acute inflammation – linking the fibroblast senescence mechanisms described in the Fibroblast entity to PIH susceptibility as a chronic rather than only post-acute risk. ^[5]